Download PDF
Exp Clin Endocrinol Diabetes 2014; 122(08): 451-456
DOI: 10.1055/s-0034-1375674
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Serum Omentin-1 Levels in Diabetic and Nondiabetic Patients with Chronic Kidney Disease

H. Tekce
1   Faculty of Medicine, Department of Internal Medicine, Abant Izzet Baysal University, Bolu, Turkey
,
B. K. Tekce
2   Faculty of Medicine, Department of Medical Biochemistry, Abant Izzet Baysal University, Bolu, Turkey
,
G. Aktas
1   Faculty of Medicine, Department of Internal Medicine, Abant Izzet Baysal University, Bolu, Turkey
,
A. Alcelik
1   Faculty of Medicine, Department of Internal Medicine, Abant Izzet Baysal University, Bolu, Turkey
,
E. Sengul
3   Department of Nephrology, Derince Education and Research Hospital, Kocaeli, Turkey
› Author Affiliations
Further Information

Publication History

received 14 February 2014
first decision 24 March 2014

accepted 29 April 2014

Publication Date:
11 June 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Omentin-1, a novel adipokine identified in visceral adipose tissue, is negatively correlated with different conditions such as diabetes, obesity and inflammation. However, changes in serum Omentin levels associated with the degree of the renal dysfunction and metabolic risk factors in CKD patients has not yet been revealed. In the present study, we aimed to investigate the level of Omentin-1 and related para­meters in diabetic and non-diabetic CKD patients.

Methods: 64 (30 diabetic, 34 non-diabetic) CKD patients and 27 healthy control subjects enrolled in this cross-sectional study. Anthropometric and laboratory assessment performed and malnutrition and inflammation components evaluated. Serum concentrations of Omentin-1 and insulin were measured by using ELISA.

Results: Serum Omentin-1 levels in CKD patients were significantly lower compared to the healthy controls. Further analyze revealed that decreased omentin in CKD patients was due to the reduced omentin levels in the diabetic subgroup. An increase in inflammation and malnutrition components was correlated with a decrease in the serum level of Omentin. Omentin levels were lower in stage 2 and 3 CKD but not stage 4 CKD patients compared to control.

Conclusions: The results of the present study suggest that diabetes mellitus and inflammation should be associated with lower omentin levels in CKD population; however, this reduction resolves due to the failure of degradation and excretion of omentin when creatinine clearance falls below 30 ml/min (stage 4 CKD).

Key words

omentin - chronic kidney disease - diabetes mellitus - inflammation
 

  • References

  • 1 Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. American journal of kidney diseases: the official journal of the National Kidney Foundation 1998; 32: S112-S119
    CrossrefPubMedGoogle Scholar
  • 2 Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transpl 2005; 20: 1048-1056
    CrossrefPubMedGoogle Scholar
  • 3 Akdag I, Yilmaz Y, Kahvecioglu S et al. Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: a 5-year prospective study. Nephron Clinical practice 2008; 108: c99-c105
    CrossrefPubMedGoogle Scholar
  • 4 Tripepi G, Mattace Raso F, Sijbrands E et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clinical journal of the American Society of Nephrology: CJASN 2011; 6: 1714-1721
    CrossrefPubMedGoogle Scholar
  • 5 Shoji T, Masakane I, Watanabe Y et al. Committee of Renal Data Registry JSfDT. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clinical journal of the American Society of Nephrology: CJASN 2011; 6: 1112-1120
    CrossrefPubMedGoogle Scholar
  • 6 Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350
    CrossrefPubMedGoogle Scholar
  • 7 de Souza Batista CM, Yang RZ, Lee MJ. et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661
    CrossrefPubMedGoogle Scholar
  • 8 Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes research and clinical practice 2010; 88: 29-33
    CrossrefPubMedGoogle Scholar
  • 9 Tan BK, Adya R, Farhatullah S et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome – Ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57: 801-808
    CrossrefPubMedGoogle Scholar
  • 10 Kazama K, Usui T, Okada M et al. Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. European Journal of Pharmacology 2012; 686: 116-123
    CrossrefPubMedGoogle Scholar
  • 11 Shibata R, Ouchi N, Takahashi R et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012; 4
    PubMedGoogle Scholar
  • 12 Auguet T, Quintero Y, Riesco D et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC medical genetics 2011; 12: 60
    PubMedGoogle Scholar
  • 13 Zhong X, Zhang HY, Tan H et al. Association of serum omentin-1 levels with coronary artery disease. Acta pharmacologica Sinica 2011; 32: 873-878
    CrossrefPubMedGoogle Scholar
  • 14 Liu R, Wang XL, Bu PL. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes research and clinical practice 2011; 93: 21-25
    CrossrefPubMedGoogle Scholar
  • 15 Shibata R, Takahashi R, Kataoka Y et al. Association of a fat-derived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men. Hypertension research: official journal of the Japanese Society of Hypertension 2011; 34: 1309-1312
    CrossrefPubMedGoogle Scholar
  • 16 Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
    Google Scholar
  • 17 Assoc AD. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2012; 35: S64-S71
    CrossrefPubMedGoogle Scholar
  • 18 Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of internal medicine 1999; 130: 461-470
    CrossrefPubMedGoogle Scholar
  • 19 Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome – the heart of the matter. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association 2002; 17 (Suppl. 11) 28-31
    PubMedGoogle Scholar
  • 20 Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22: C10-C13
    CrossrefPubMedGoogle Scholar
  • 21 Yang RZ, Lee MJ, Hu H et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol-Endoc M 2006; 290: E1253-E1261
    PubMedGoogle Scholar
  • 22 Schaffler A, Neumeier M, Herfarth H et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochimica et biophysica acta 2005; 1732: 96-102
    CrossrefPubMedGoogle Scholar
  • 23 Yamawaki H, Tsubaki N, Mukohda M et al. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochemical and biophysical research communications 2010; 393: 668-672
    CrossrefPubMedGoogle Scholar
  • 24 Yoo HJ, Hwang SY, Hong HC et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovascular diabetology 2011; 10: 103
    CrossrefPubMedGoogle Scholar
  • 25 Choi JH, Rhee EJ, Kim KH et al. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. European journal of endocrinology/European Federation of Endocrine Societies 2011; 165: 789-796
    CrossrefPubMedGoogle Scholar
  • 26 Tan BK, Pua S, Syed F et al. Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabetic medicine: a journal of the British Diabetic Association 2008; 25: 1254-1255
    CrossrefPubMedGoogle Scholar
  • 27 Tan BK, Adya R, Randeva HS. Omentin: A Novel Link Between Inflammation, Diabesity, and Cardiovascular Disease. Trends Cardiovas Med 2010; 20: 143-148
    CrossrefPubMedGoogle Scholar
  • 28 Moreno-Navarrete JM, Ortega F, Castro A et al. Circulating Omentin as a Novel Biomarker of Endothelial Dysfunction. Obesity 2011; 19: 1552-1559
    CrossrefPubMedGoogle Scholar
  • 29 Moreno-Navarrete JM, Catalan V, Ortega F et al. Circulating omentin concentration increases after weight loss. Nutrition & metabolism 2010; 7: 27
    CrossrefPubMedGoogle Scholar
  • 30 Shaker M, Mashhadani ZI, Mehdi AA. Effect of Treatment with Metformin on Omentin-1, Ghrelin and other Biochemical, Clinical Features in PCOS Patients. Oman medical journal 2010; 25: 289-293
    PubMedGoogle Scholar
  • 31 Alcelik A, Tosun M, Ozlu MF et al. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press Res 2012; 35: 511-516
    CrossrefPubMedGoogle Scholar
  • 32 Shinohara K, Shoji T, Emoto M et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894-1900
    CrossrefPubMedGoogle Scholar
  • 33 Zanetti M, Barazzoni R, Guarnieri G. Inflammation and insulin resistance in uremia. Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation 2008; 18: 70-75
    CrossrefPubMedGoogle Scholar
  • 34 Oberg BP, McMenamin E, Lucas FL et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney international 2004; 65: 1009-1016
    CrossrefPubMedGoogle Scholar
  • 35 Mathur S, Devaraj S, Jialal I. Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease. Current opinion in nephrology and hypertension 2002; 11: 141-147
    CrossrefPubMedGoogle Scholar
  • 36 El-Mesallamy H, El-Derany M, Hamdy N. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabetic Medicine 2011; 28: 1194-1200
    CrossrefPubMedGoogle Scholar
  • 37 Tan BK, Adya R, Farhatullah S et al. Metformin Treatment May Increase Omentin-1 Levels in Women With Polycystic Ovary Syndrome. Diabetes 2010; 59: 3023-3031
    CrossrefPubMedGoogle Scholar
  • 38 Zhong X, Li X, Liu F et al. Omentin inhibits TNF-alpha-induced expression of adhesion molecules in endothelial cells via ERK/NF-kappaB pathway. Biochemical and biophysical research communications 2012; 425: 401-406
    CrossrefPubMedGoogle Scholar
  • 39 Schaffler A, Zeitoun M, Wobser H et al. Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in the human gene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel diseases. Cardiovascular diabetology 2007; 6: 3
    CrossrefPubMedGoogle Scholar
  • 40 Senolt L, Polanska M, Filkova M et al. Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1410-1411
    CrossrefPubMedGoogle Scholar